DiaMedica Therapeutics Statistics
Total Valuation
DMAC has a market cap or net worth of $181.83 million. The enterprise value is $143.11 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DMAC has 42.88 million shares outstanding. The number of shares has increased by 17.44% in one year.
| Current Share Class | 42.88M |
| Shares Outstanding | 42.88M |
| Shares Change (YoY) | +17.44% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 38.58% |
| Owned by Institutions (%) | 17.76% |
| Float | 24.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.30 |
| P/TBV Ratio | 5.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.02, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.02 |
| Quick Ratio | 7.84 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.25% and return on invested capital (ROIC) is -44.88%.
| Return on Equity (ROE) | -67.25% |
| Return on Assets (ROA) | -41.27% |
| Return on Invested Capital (ROIC) | -44.88% |
| Return on Capital Employed (ROCE) | -85.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$964,286 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DMAC has paid $29,000 in taxes.
| Income Tax | 29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.73% in the last 52 weeks. The beta is 1.29, so DMAC's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | +43.73% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 4.73 |
| Relative Strength Index (RSI) | 54.14 |
| Average Volume (20 Days) | 112,971 |
Short Selling Information
The latest short interest is 856,926, so 2.00% of the outstanding shares have been sold short.
| Short Interest | 856,926 |
| Short Previous Month | 619,688 |
| Short % of Shares Out | 2.00% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 8.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.08M |
| Pretax Income | -19.85M |
| Net Income | -27.00M |
| EBITDA | -29.04M |
| EBIT | -29.08M |
| Earnings Per Share (EPS) | -$0.65 |
Full Income StatementBalance Sheet
The company has $36.32 million in cash and $316,000 in debt, giving a net cash position of $37.00 million or $0.86 per share.
| Cash & Cash Equivalents | 36.32M |
| Total Debt | 316,000 |
| Net Cash | 37.00M |
| Net Cash Per Share | $0.86 |
| Equity (Book Value) | 33.95M |
| Book Value Per Share | 0.79 |
| Working Capital | 32.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.57 million and capital expenditures -$28,000, giving a free cash flow of -$22.60 million.
| Operating Cash Flow | -22.57M |
| Capital Expenditures | -28,000 |
| Free Cash Flow | -22.60M |
| FCF Per Share | -$0.53 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.44% |
| Shareholder Yield | -17.44% |
| Earnings Yield | -14.99% |
| FCF Yield | -12.55% |
Analyst Forecast
The average price target for DMAC is $8.00, which is 88.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 88.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 15, 2018. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Nov 15, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |